Evidence map›Paper›PMID 39579167›Full record

ArticleDiscover oncology2024

Tumor analysis of BRCA carriers reveals genomic similarities although separated by time.

Tal Falick Michaeli, Avital Granit Mizrahi, Batia Azria, Ofra Maymon, Shai Rosenberg, Jonathan Monin, Esther Braitbart Cohen, Myriam Maoz, Luna Kadiuri, Hovav Nechushtan and 2 more

Abstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tal Falick MichaeliDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University Medical School, 91120, Jerusalem, Israel. tal.michaeli@mail.huji.ac.il.
Avital Granit MizrahiSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Batia AzriaDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University Medical School, 91120, Jerusalem, Israel.
Ofra MaymonSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Shai RosenbergSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Jonathan MoninDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University Medical School, 91120, Jerusalem, Israel.
Esther Braitbart CohenSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Myriam MaozSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Luna KadiuriSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Karem, 91120, Jerusalem, Israel.
Hovav NechushtanDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University Medical School, 91120, Jerusalem, Israel.
Amichay Meyrowitz *Soroka Medical Center, 84101, Be'er Sheva, Israel.
Tamar Peretz *Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University Medical School, 91120, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the dominant pathogenic genes (PG) in breast cancer are BRCA1/2. Knowing whether a patient carry one of these alterations is meaningful as it affects management. A substantial question is to what extent are the genomic profile of a tumor and its characteristics affected by the germline profile of BRCA1/2 and what is the possible contribution of other environmental factors. Here, we compared the molecular characteristics of two subsequent primary breast cancers in three women (6 primary breast cancers) BRCA PG carriers, and in two of them also a primary lung cancer. Comparing two different tumors in the same patient neutralizes the contribution of other germline changes, and may demonstrate possible effects of other external insults occurring between the first and second tumor. Nonetheless, epigenetic changes resulting from early life events will be present in all tumors that the patient has developed. Our analysis suggests that tumors arising from the same tissue in the same patient share similar molecular characteristics, albeit occurring in different times, as the patient is exposed to a variety of external stimuli.

Indexed as

BRCA1/2 carriersBreast cancerExome analysisMolecular signatureSecond primary

Identifiers

PMID39579167
PMCPMC11585525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.